Cathepsin K inhibitors: A novel target for osteoporosis therapy

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 1, 2008, Pages 172-176

  Stoch, S A ^a   Wagner, J A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BALICATIB; BENZAMIDE DERIVATIVE; CATHEPSIN K; CATHEPSIN K INHIBITOR; COLLAGEN TYPE 1; CYSTEINE PROTEINASE; L 006235; MK 0822; ODANACATIB; OSTEONECTIN; OSTEOPONTIN; RELACATIB; UNCLASSIFIED DRUG;

BONE BIOPSY; BONE DENSITY; BONE MARROW CULTURE; BONE MASS; CHEMICAL ANALYSIS; CLINICAL TRIAL; DEMINERALIZATION; DOSE RESPONSE; DRUG WITHDRAWAL; HUMAN; MORPHEA; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; RASH; REVIEW; SCLERODERMA; THYROPARATHYROIDECTOMY; TRANSGENIC MOUSE;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CATHEPSINS; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; MICE; MICE, KNOCKOUT; OSTEOSCLEROSIS; OVARIECTOMY; PRIMATES; RABBITS; RATS; TREATMENT OUTCOME;

EID: 37549068912     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100450     Document Type: Review

References (34)

1. Troen, B.R. The role of cathepsin K in normal bone resorption. Drug News Perspect. 70, 19-28 (2004).
2. Gelb, B.D., Shi, G.P., Chapman, H.A. & Desnick, R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273, 1236-1238 (1996).
3. Bossard, M., Tomazek, T.A. & Thompson, S. Proteolytic activity of human osteoclast cathepsin K. J. Biol. Chem. 271, 12517-12524 (1996).
4. Tezuka, K. et al. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J. Biol. Chem. 269, 2126-2132 (1994).
5. Inui, T. et al. Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J. Biol. Chem. 272, 8109-8112 (1997).
6. Vaes, G. On the mechanisms of bone resorption. J. Cell Biol. 39, 676-697 (1980).
7. Littlewood-Evans, A., Kokubo, O., Inaoka, T., Wlodarski, B., Gallagher, J.A. & Bilbe, G. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 20, 81-86 (1997).
8. Yamaza, T., Goto, T., Kamiya, T., Kobayashi, Y., Sakai, H. & Tanaka, T. Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur. Bone 23, 499-509 (1998).
9. Marquis, R.W. Inhibition of the cysteine protease cathepsin K. Annu. Rep. Med. Chem. 39, 79-98 (2004).
10. Li, C.S. et al. Identification of a potent and selective non-basic cathepsin K inhibitor. Bioorg. Med. Chem. Lett. 16, 1985-1989 (2006).
11. Votta, B.J. et al. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J. Bone Miner. Res. 12, 1396-1406 (1997).
12. Flanagan, A. & Sarma, U. In Methods in Bone Biology (eds. Arnett, T.R. & Henderson, B.) (Chapman & Hall, London, 1998).
13. James, I.E., Lark, M. & Zembryki, D. Development and characterization of a human in vitro resorption assay: demonstration of utility using novel antiresorptive agents. J. Bone Miner. Res. 14, 1562-1569 (1992).
14. Guay, J., Riendeau, D. & Mancini, J.A. Cloning and expression of rhesus monkey cathepsin K. Bone 25, 205-209 (1999).
15. Binkley, N., Kimmel, D.B. & Bruner, J. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J. Bone Miner. Res. 13, 1775-1782 (1998).
16. Lazner, F. Gowen, M. & Kola, I. An animal model of pycnodysostosis: the role of cathepsin K in bone remodeling. Mol. Med.Today 5, 413-414 (1999).
17. Saftig, P. et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Biochemistry 95, 13453-13458 (1998).
18. Pennypacker, B. et al. Bone density, and strength in cathepsin K mice. J. Bone Miner. Res. 14, S549 (1999).
19. Kiviranta, R. Morko, J. Uusitalo, H. Aro, H.T. Vuorio, E. & Rantakokko, J. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J. Bone Miner. Res.16, 1444-1452 (2001).
20. Marquis, R.W. et al. Azepanone-based inhibitors of human and rat cathepsin K. J. Med. Chem. 44, 1380-1395 (2001).
21. Yasuma, T. et al. Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L, and their inhibitory effect on bone resorption. J. Med. Chem. 41, 4301-4308 (1998).
22. Fisher, J.E. et al. Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein. Endocrinology 132, 1411-1413 (1993).
23. Lark, M.W. et al. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone 30, 746-753 (2002).
24. Pennypacker, B., Rodan, S., Masarachia, P., Rodan, G. & Kimmel, D.B. Bone effects of a cathepsin K inhibitor in the adult estrogen deficient rabbit. J. Bone Miner. Res. 21, S303 (2006).
25. Pennypacker, B. et al. Bone effects of cathepsin K inhibitors in the growing rabbit. J. Bone Miner. Res. 21, S304 (2006).
26. Palmer, J.T. et al. Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J. Med. Chem. 48, 7520-7534 (2005).
27. Stroup, G.B., Dare, L., Vasko-Moser, J., Hoffman, S. & Kumar, S. Repeat daily dosing with a highly potent inhibitor of cathepsin K results in significant, transient elevation in PTH in cynomolgus monkeys. J. Bone Miner. Res. 21, S160 (2006).
28. Stoch, S.A. et al. Effect of cathepsin K inhibition on bone resorption markers in healthy postmenopausal women. J. Bone Miner. Res. 21, S60 2006).
29. Stoch, S.A. et al. Cathepsin K inhibition reduces bone resorption biomarkers in healthy postmenopausal women. Amer. Soc. Clin. Pharm. Therap. P59 (2007).
30. Bone, H.G. et al. A randomized double-blind, placebo-controlled study of a cathepsin K inhibitor in the treatment of postmenopausal women with low BMD one-year results. J. Bone. Miner. Res. S37 (2007).
31. Papanastasiou, P., Ortmann, C.E., Olson, M., Vigneron, A. & Trechsel, U. Effect of three months treatment with the cathepsin-K inhibitor, Balicatib, on biochemical markers of bone turnover in postmenopausal women: evidence for uncoupling of bone resorption and bone formation. J. Bone Miner. Res. 21, S59 (2006).
32. Adami, S. et al. Effect of one year treatment with the cathepsin-K inhibitor, Balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. J. Bone Miner. Res. 21, S24 (2006).
33. Nishi, Y. et al. Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation. J. Bone Miner. Res. 14, 1902-1908 (1999).
34. Fratzl-Zelman, N. et al. Decreased bone turnover in deterioration of bone structure in two cases in pycnodysostosis. J. Clin. Endocrinol. Metab. 89, 1538-1547 (2004).